Phio Pharmaceuticals Corp.
PHIO
$1.99
-$0.10-4.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.72M | 2.51M | 2.48M | 2.51M | 3.67M |
| Gross Profit | -2.72M | -2.51M | -2.48M | -2.51M | -3.67M |
| SG&A Expenses | 3.86M | 3.67M | 3.74M | 3.82M | 3.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.45M | 7.05M | 7.39M | 7.49M | 8.67M |
| Operating Income | -7.45M | -7.05M | -7.39M | -7.49M | -8.67M |
| Income Before Tax | -7.09M | -6.77M | -7.15M | -7.42M | -8.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.09 | -6.77 | -7.15 | -7.42 | -8.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.09M | -6.77M | -7.15M | -7.42M | -8.68M |
| EBIT | -7.45M | -7.05M | -7.39M | -7.49M | -8.67M |
| EBITDA | -7.44M | -7.05M | -7.39M | -7.47M | -8.65M |
| EPS Basic | -3.83 | -7.00 | -7.06 | -11.30 | -20.01 |
| Normalized Basic EPS | -2.39 | -4.37 | -4.41 | -6.82 | -12.27 |
| EPS Diluted | -3.83 | -7.00 | -7.06 | -11.30 | -20.01 |
| Normalized Diluted EPS | -2.39 | -4.37 | -4.41 | -6.82 | -12.27 |
| Average Basic Shares Outstanding | 11.23M | 6.94M | 7.22M | 6.41M | 5.70M |
| Average Diluted Shares Outstanding | 11.23M | 6.94M | 7.22M | 6.41M | 5.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |